Contact details
Phyllis Spuls
Main
Louise Gerbens
Alternate
Publications
Data source publications
- Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry
- Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema Registry Taskforce
- The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort study
- Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types
- Work ability and quality of working life in atopic dermatitis patients treated with dupilumab
- The Selection Process for a Web-Based Application to Measure Patient-Reported Outcomes Following the Example of the TREAT NL Registry
- Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data
- Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series
- Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”
- TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema
- Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry